Search Results - "Iezzi, Alice"

  • Showing 1 - 6 results of 6
Refine Results
  1. 1
    Generation and characterization of MEK and ERK inhibitors- resistant non-small-cells-lung-cancer (NSCLC) cells

    Generation and characterization of MEK and ERK inhibitors- resistant non-small-cells-lung-cancer (NSCLC) cells by Iezzi, Alice, Caiola, Elisa, Scagliotti, Arianna, Broggini, Massimo

    Published in BMC cancer (23-10-2018)
    “…The RAS/RAF/MEK/ERK pathway is one of the most downregulated pathway in cancer. Inhibitors of RAF and MEK have established clinical use while ERK inhibitors…”
    Get full text
    Journal Article
    Save to List
    Saved in:
  2. 2
    Activity of Pan-Class I Isoform PI3K/mTOR Inhibitor PF-05212384 in Combination with Crizotinib in Ovarian Cancer Xenografts and PDX

    Activity of Pan-Class I Isoform PI3K/mTOR Inhibitor PF-05212384 in Combination with Crizotinib in Ovarian Cancer Xenografts and PDX by Iezzi, Alice, Caiola, Elisa, Broggini, Massimo

    Published in Translational oncology (01-10-2016)
    “…Abstract The Phosphatidyl inositol-3 kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) and c-Met signaling pathways are often deregulated in cancer. The…”
    Get full text
    Journal Article
    Save to List
    Saved in:
  3. 3
    LKB1 Deficiency Renders NSCLC Cells Sensitive to ERK Inhibitors

    LKB1 Deficiency Renders NSCLC Cells Sensitive to ERK Inhibitors by Caiola, Elisa, Iezzi, Alice, Tomanelli, Michele, Bonaldi, Elisa, Scagliotti, Arianna, Colombo, Marika, Guffanti, Federica, Micotti, Edoardo, Garassino, Marina Chiara, Minoli, Lucia, Scanziani, Eugenio, Broggini, Massimo, Marabese, Mirko

    Published in Journal of thoracic oncology (01-03-2020)
    “…Serine/threonine kinase 11 (LKB1/STK11) is one of the most mutated genes in NSCLC accounting for approximately one-third of cases and its activity is impaired…”
    Get more information
    Journal Article
    Save to List
    Saved in:
  4. 4
    Wee1 inhibitor MK1775 sensitizes KRAS mutated NSCLC cells to sorafenib

    Wee1 inhibitor MK1775 sensitizes KRAS mutated NSCLC cells to sorafenib by Caiola, Elisa, Frapolli, Roberta, Tomanelli, Michele, Valerio, Rossana, Iezzi, Alice, Garassino, Marina C., Broggini, Massimo, Marabese, Mirko

    Published in Scientific reports (17-01-2018)
    “…Non-Small-Cell Lung Cancer (NSCLC) is a poorly chemosensitive tumor and targeted therapies are only used for about 15% of patients where a specific driving and…”
    Get full text
    Journal Article
    Save to List
    Saved in:
  5. 5
    Molecular determinants of response to PI3K/akt/mTOR and KRAS pathways inhibitors in NSCLC cell lines

    Molecular determinants of response to PI3K/akt/mTOR and KRAS pathways inhibitors in NSCLC cell lines by Iezzi, Alice, Caiola, Elisa, Colombo, Marika, Marabese, Mirko, Broggini, Massimo

    Published in American journal of cancer research (01-01-2020)
    “…Despite the impressive results obtained in the preclinical setting, all the inhibitors targeting two central cascades in cancer, the PI3K/akt/mTOR and the…”
    Get full text
    Journal Article
    Save to List
    Saved in:
  6. 6
    Activity of Pan-Class I Isoform PI3K/mTOR Inhibitor PF-05212384 in Combination with Crizotinib in Ovarian Cancer Xenografts and PDX1

    Activity of Pan-Class I Isoform PI3K/mTOR Inhibitor PF-05212384 in Combination with Crizotinib in Ovarian Cancer Xenografts and PDX1 by Iezzi, Alice, Caiola, Elisa, Broggini, Massimo

    Published in Translational oncology (14-10-2016)
    “…The Phosphatidyl inositol-3 kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) and c-Met signaling pathways are often deregulated in cancer. The two…”
    Get full text
    Journal Article
    Save to List
    Saved in:

Search Tools: